Phase III, Double Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer. (PACES) (SWOG S0820)

Study Details

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. The primary hypothesis will test the main effect of each agent, as well as the comparison of placebo alone to the combination of sulindac and eflornithine.

Learn More

ClinicalTrials.gov NCT number
NCT01349881

Principal Investigators

  • Salvatore Del Prete, MD
Sponsor(s)
Southwest Oncology Group
Contact
Ed Hatton, RN at 203-358-8879
or officeofresearch@stamhealth.org

Location

  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695